RTX vs TMO: Which Is the Better Buy?
Side-by-side comparison of RTX Corporation and Thermo Fisher Scientific Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
RTX Corporation · Industrials
$185.60
-25.2% upside to fair value
Grade D
VS
Thermo Fisher Scientific Inc. · Healthcare
$464.61
+7.2% upside to fair value
Grade A
High Quality
QuantHub Verdict
TMO has more upside to fair value
(+7.2%).
TMO trades at a lower forward P/E
(25.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
RTX |
TMO |
| Current Price |
$185.60 |
$464.61 |
| Fair Value Estimate |
$138.81 |
$498.27 |
| Upside to Fair Value |
-25.2%
|
+7.2%
|
| Market Cap |
$249.9B |
$172.7B |
| Forward P/E |
34.3x
|
25.2x
|
| EV / EBITDA |
18.3x
|
19.1x
|
| Price / Sales |
2.8x
|
3.8x
|
| Price / FCF |
29.9x
|
25.6x
|
| Revenue Growth YoY |
+8.7%
|
+6.2%
|
| Gross Margin |
20.2%
|
39.4%
|
| Operating Margin |
10.9%
|
17.8%
|
| Return on Equity |
11.2%
|
13.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.34%
|
3.91%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
RTX Corporation is a leading aerospace and defense company with a strong competitive moat driven by scale and an installed base in commercial aerospace via Pratt & Whitney and Collins Aerospace, and defense through Raytheon. The company benefits from a large multi-year backlog of approximately $270 billion supporting steady cash flow and mid-single-digit organic growth. Despite solid revenue grow…
Thermo Fisher Scientific is a leading healthcare company specializing in life science tools, diagnostics, and contract research and manufacturing services. It operates with a broad, multi-layered moat driven by scale, integration, and a long-tenured management team. The company exhibits solid fundamentals with a 13.3% ROE, 6.2% revenue growth, and 9.6% earnings growth in the most recent quarter. …
Accumulation Zones
| Metric |
RTX |
TMO |
| Zone Low |
$104.11 |
$373.70 |
| Zone High |
$117.99 |
$423.53 |
| In Buy Zone? |
No
|
No
|